Actively Recruiting
Safety, Tolerability, and Efficacy of LBL-034 in RelapsedRefractory Multiple Myeloma Patients An Open-label Multicenter Phase III Study Evaluating Intravenous LBL-034 Treatment
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-09-11
342
Participants Needed
21
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying LBL-034 in patients with relapsed or refractory multiple myeloma RRMM and plasma cell leukemia PCL to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and effectiveness. This open-label, multicenter phase III study includes dose escalation and dose expansion phases to find the recommended dose and dosing schedule. The trial aims to assess treatment response and adverse events in these patients. LBL-034 is given as an intravenous infusion every two weeks. The phase I study involves dose escalation to assess safety and tolerability, including a dose-limiting toxicity observation period lasting four weeks after the first full dose. After determining the recommended phase 2 dose RP2D, the phase II study evaluates efficacy across four patient cohorts, with dosing regimens based on phase I data. Biological samples are collected throughout for additional testing. Participants will be monitored for treatment response, drug levels, immune reaction, and side effects from the time they consent until 30 to 90 days after stopping the drug. Evaluation includes measurement of objective response rate, dose-limiting toxicities, maximum tolerated dose, adverse events, and other key outcomes such as minimal residual disease and soluble BCMA levels. The study will enroll approximately 342 patients and continues until 2027.
CONDITIONS
Brief Title
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Research Team
J
jin lu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here